Arecor Therapeutics PLC (AIM:AREC)'s subsidiary Tetris Pharma has partnered exclusively with a company called Goodlife, which will import, market and distribute the diabetes treatment Ogluo in the Benelux region.
With the regulatory green light from the Zorginstiuut Nederland, the National Healthcare Institute of The Netherlands, Goodlife is poised to launch Ogluo in the Dutch market by the first half of next year.
Chief executive Sarah Howell told investors: "Goodlife provides the commercial expertise and detailed understanding of regional market dynamics that are essential for the company's continued roll-out of Ogluo and its market adoption in the Benelux region.
"The upcoming launch in The Netherlands adds to existing markets in the UK, Germany, Austria, Denmark and Norway, as part of the planned ongoing pan-European commercial roll-out for this important product."
Ogluo, a user-friendly auto-injector pen, can be stored at room temperature and was granted marketing authorisation by the European Commission in February 2021.